-
Je něco špatně v tomto záznamu ?
Carbonyl Reduction of Flubendazole in the Human Liver: Strict Stereospecificity, Sex Difference, Low Risk of Drug Interactions
V. Kubíček, L. Skálová, A. Skarka, V. Králová, J. Holubová, J. Štěpánková, Z. Šubrt, B. Szotáková,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
31191322
DOI
10.3389/fphar.2019.00600
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Flubendazole (FLU), an anthelmintic drug of benzimidazole type, is now considered a promising anti-cancer agent due to its tubulin binding ability and low system toxicity. The present study was aimed at determining more information about FLU reduction in human liver, because this information has been insufficient until now. Subcellular fractions from the liver of 12 human patients (6 male and 6 female patients) were used to study the stereospecificity, cellular localization, coenzyme preference, enzyme kinetics, and possible inter-individual or sex differences in FLU reduction. In addition, the risk of FLU interaction with other drugs was evaluated. Our study showed that FLU is predominantly reduced in cytosol, and the reduced nicotinamide adenine dinucleotide phosphate (NADPH) coenzyme is preferred. The strict stereospecificity of FLU carbonyl reduction was proven, and carbonyl reductase 1 was identified as the main enzyme of FLU reduction in the human liver. A higher reduction of FLU and a higher level of carbonyl reductase 1 protein were found in male patients than in female patients, but overall inter-individual variability was relatively low. Hepatic intrinsic clearance of FLU is very low, and FLU had no effect on doxorubicin carbonyl reduction in the liver and in cancer cells. All these results fill the gaps in the knowledge of FLU metabolism in human.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028894
- 003
- CZ-PrNML
- 005
- 20190819105851.0
- 007
- ta
- 008
- 190813s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2019.00600 $2 doi
- 035 __
- $a (PubMed)31191322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kubíček, Vladimír $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 245 10
- $a Carbonyl Reduction of Flubendazole in the Human Liver: Strict Stereospecificity, Sex Difference, Low Risk of Drug Interactions / $c V. Kubíček, L. Skálová, A. Skarka, V. Králová, J. Holubová, J. Štěpánková, Z. Šubrt, B. Szotáková,
- 520 9_
- $a Flubendazole (FLU), an anthelmintic drug of benzimidazole type, is now considered a promising anti-cancer agent due to its tubulin binding ability and low system toxicity. The present study was aimed at determining more information about FLU reduction in human liver, because this information has been insufficient until now. Subcellular fractions from the liver of 12 human patients (6 male and 6 female patients) were used to study the stereospecificity, cellular localization, coenzyme preference, enzyme kinetics, and possible inter-individual or sex differences in FLU reduction. In addition, the risk of FLU interaction with other drugs was evaluated. Our study showed that FLU is predominantly reduced in cytosol, and the reduced nicotinamide adenine dinucleotide phosphate (NADPH) coenzyme is preferred. The strict stereospecificity of FLU carbonyl reduction was proven, and carbonyl reductase 1 was identified as the main enzyme of FLU reduction in the human liver. A higher reduction of FLU and a higher level of carbonyl reductase 1 protein were found in male patients than in female patients, but overall inter-individual variability was relatively low. Hepatic intrinsic clearance of FLU is very low, and FLU had no effect on doxorubicin carbonyl reduction in the liver and in cancer cells. All these results fill the gaps in the knowledge of FLU metabolism in human.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Skálová, Lenka $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Skarka, Adam $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia.
- 700 1_
- $a Králová, Věra $u Department of Biology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Holubová, Jana $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Štěpánková, Jana $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 700 1_
- $a Šubrt, Zdeněk $u Department of Surgery, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czechia. Department of Surgery, University Hospital Hradec Králové, Hradec Králové, Czechia.
- 700 1_
- $a Szotáková, Barbora $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 10, č. - (2019), s. 600
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31191322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819110125 $b ABA008
- 999 __
- $a ind $b bmc $g 1434043 $s 1067354
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 10 $c - $d 600 $e 20190528 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20190813